Cardiac Dimensions announced that it has initiated European commercialisation of its Carillon Mitral Contour System used in the treatment of patients suffering from functional mitral regurgitation (FMR).
The US Food and Drug Administration (FDA) has given clearance to Boston Scientific for its Emerge Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter. The company has begun marketing the device in the United States.
Medtronic has announced that it has received the CE mark for its CoreValve Evolut 23mm valve, its latest self-expanding transcatheter aortic valve implantation (TAVI) system.
Stentys has released in Europe an enhanced stent-delivery system for its Self-Apposing Stent used in the treatment of acute myocardial infarction (AMI).
On 25 September, Abbott announced that Absorb, the world’s first drug-eluting bioresorbable vascular scaffold (BVS), is now widely available across Europe and parts of Asia Pacific and Latin America.
A study lead by researchers from the Mount Sinai Medical Center in Miami, USA, has found that patients with coronary valvular disease who were treated with a hybrid approach combining coronary artery stenting with minimally invasive valve surgery showed significantly better outcomes than patients who had standard sternotomy coronary bypass and valve surgery.
Acute results from preclinical studies of the Tiara valve (Neovasc) for the transcatheter treatment of mitral regurgitation have shown that implantation of Tiara valves was feasible, relatively straightforward and resulted in a securely-implanted, well-functioning device that maintained good haemodynamics in the test animals.
Madrid, septiembre de 2012.- En España hay actualmente un millón de personas que siguen una terapia anticoagulante oral; de ellas, cerca de 700.000 reciben tratamiento crónico y el resto uno temporal, en función de la necesidad que presenten de mantener los niveles de coagulación adecuados y de la causa de su problema.
Cardionovum has announced positive initial results of a preclinical study and a first-in-man clinical study of its Primus Drug-Coated Balloon (DCB).
Boston Scientific has signed a definitive agreement to acquire BridgePoint Medical, developer of a proprietary, catheter-based system to treat coronary chronic total occlusions (CTOs).
España, septiembre de 2012.- Una nueva forma de abordar el infarto agudo de miocardio (IAM) en sus primeros momentos basada en estudios realizados por investigadores españoles de la RECAVA (Red de Investigación Cardiovascular) es la que recomiendan las nuevas Guías de Actuación en IAM de la Sociedad Europea de Cardiología.
Sorin Group has announced it has received CE mark approval for extended indications of Perceval S, as well as for an entirely re-designed 2nd generation set of implantation accessories. Perceval S is a bioprosthetic valve designed to replace a diseased native or malfunctioning prosthetic aortic valve via open heart surgery with the unique characteristic of allowing sutureless positioning and anchoring at the implantation site.
Madrid, septiembre de 2012.- Según el último estudio realizado por Thomson Reuters sobre el factor de impacto de las principales publicaciones científicas, Journal Citacions Report (JCR), Revista Española de Cardiología (REC) es la revista escrita en lengua española más influyente y más consultada.
Abiomed has received 510(k) clearance from the FDA for a new percutaneous, catheter-based Impella device providing peak flows of approximately four liters of blood per minute. The increased flow is delivered on the same console platform, 9 French catheter, and introducer as the Impella 2.5. This new heart pump will be marketed as the Impella CP (Cardiac Power) within the United States and has been commercially known outside the US as the Impella cVAD.
The Society for Cardiovascular Angiography and Interventions (SCAI) has launched the new SCAI Quality Improvement Toolkit (SCAI-QIT) Appropriate Use Criteria (AUC) and Guidelines app designed to provide information on coronary revascularisation appropriate use criteria.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos